Developer docs
API playgroundTry for free, no card

Search company profiles

Sinopharm

Full company profile

uuid003bk84

Namestring
Sinopharm
Legal namestring
国药集团工业有限公司
Websiteurl
cnpicl.com
Company typeenum
Public
Founded yearint
1991
Descriptiontext

Sinopharm Group Industrial Co., Ltd. (国药集团工业有限公司) is a Chinese state-designated pharmaceutical manufacturer founded in 1991 and headquartered in Shunyi, Beijing. It operates as a wholly-owned subsidiary of Shanghai Modern Pharmaceutical Co., Ltd. (国药现代, Shanghai Stock Exchange ticker 600420) under China National Pharmaceutical Group Co., Ltd. (Sinopharm Group), and is ultimately owned by China's State-owned Assets Supervision and Administration Commission (SASAC). The company operates two production bases — Shunyi (Beijing, approximately 100,000 square meters of total land area) and Langfang (Hebei Province, secondary manufacturing base) — and is the national designated manufacturer of narcotic and psychotropic pharmaceutical products in China.

The company's product portfolio spans anesthesia, analgesia, antitussive, cardiovascular, psychiatric, gynecological suppository, and other therapeutic areas, produced under an integrated API-formulation production system. Annual production capacity includes approximately 60 tons of active pharmaceutical ingredients, 50 billion solid oral tablets, 23 million units of small-volume injections and lyophilized powder injections, and 4 million units of oral solutions, plus suppositories and other dosage forms. Core technology platforms include sustained-release microspheres, microreactor technology, chromatographic separation and purification, and impurity reference material preparation, with multiple national invention patents in anesthesia and psychotropic drugs. Recent new product launches (2025-2026) include hydromorphone hydrochloride injection (second domestic manufacturer in China), quetiapine fumarate extended-release tablets (200mg and 300mg), penehyclidine hydrochloride injection, and several new API registrations including ketamine hydrochloride and nalbuphine hydrochloride.

The company's business model is sales-led B2B distribution, organized through four regional sales divisions covering North, East, West, and South China, plus dedicated product-line divisions for anesthesia, analgesics, and commercial management. Revenue is generated through direct sales to domestic healthcare institutions (hospitals, clinics) and retail pharmacy terminals, as well as API/intermediate supply to downstream pharmaceutical manufacturers, with pricing negotiated through government tendering, reimbursement lists, and institutional purchasing agreements. A separate revenue stream arises from registration certificates and consistent-evaluation approvals granted by China's National Medical Products Administration (NMPA), which expand the company's marketable product portfolio.

Short descriptiontext

Sinopharm Group Industrial Co., Ltd. is a Chinese state-designated pharmaceutical manufacturer producing narcotic, psychotropic, anesthetic, and analgesic APIs and formulations, operating dual Beijing-Hebei production bases to supply hospitals, retail pharmacies, and drug manufacturers across China.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBeijing, China
HQ citystring
Beijing
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical manufacturing, narcotic drug production, active pharmaceutical ingredients, anesthesia and analgesia, controlled substance manufacturing
Industry3 codes
PRIMARYHLAGAHAD
Controlled Substances / DEA-Scheduled API Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIAJAO
Compounding Ingredient & API Distributors (Pharma Supply)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Medicinal and Botanical Manufacturing325411
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Manufacturing
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical Manufacturing and Sales
TypeOne Time License
Description

Manufactures and sells pharmaceutical products including active pharmaceutical ingredients (APIs), solid oral formulations (50 billion tablets annually), small-volume injections and lyophilized powder injections (23 million units annually), oral solutions (4 million units annually), suppositories, and other dosage forms. Products span anesthesia, analgesia, antitussive, cardiovascular, psychiatric, and other therapeutic areas. Revenue is generated through direct sales to healthcare institutions and retail pharmacy distribution networks across China.

cnpicl.com
2New Drug Product Registrations
TypeLicensing Royalties
Description

Generates revenue through registration certificates for new drug products and API approvals from China's National Medical Products Administration (NMPA), including consistent evaluation certifications for generic drugs, expanding the company's product portfolio and market competitiveness.

cnpicl.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels7 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Sinopharm Group Industrial Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) and finished pharmaceutical products including narcotic and psychotropic drugs, anesthesia agents, analgesics, antitussives, cardiovascular medications, and gynecological suppositories across multiple dosage forms (solid oral tablets, injections, oral solutions, suppositories). The company holds national designated manufacturer status for narcotic drugs in China and supplies healthcare institutions and retail pharmacy networks through regional sales divisions covering North, East, West, and South China. Production is supported by four proprietary technology platforms including sustained-release microspheres, microreactors, chromatographic purification, and impurity reference material preparation.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Annual production capacity of ~60 tons of active pharmaceutical ingredients and 50 billion solid oral tablets
+2 more records
Product overview1 text field

Sinopharm Group Industrial Pharmaceutical Co., Ltd. (国药集团工业有限公司) is a state-designated narcotic drug manufacturing enterprise and wholly-owned subsidiary of Shanghai Sine Pharmaceutical Co., Ltd. (stock code: 600420) under China National Pharmaceutical Group (Sinopharm). The company operates two production bases in Shunyi and Langfang with approximately 100,000 square meters. Annual production capacity includes nearly 60 tons of APIs, 5 billion tablets of solid oral formulations, 23 million units of small-volume injections and freeze-dried powder injections, 4 million units of oral solutions, plus various other dosage forms including suppositories and ironing agents. The company's product portfolio centers on 'one narcotics, three analgesics, one戒 (addiction treatment)' principle, establishing an integrated production system combining narcotic APIs with preparations and full coverage of various dosage forms. The company focuses on anesthesia, analgesia, cough suppression, gynecological suppositories, and cardiovascular therapeutic areas. The company operates with raw material medicine and narcotic preparations supporting each other, with comprehensive dosage form coverage.

Product and service7 records
1Cardiovascular and Cerebrovascular Medications (心脑血管类药品)
CategoryTherapeutic drug category - Cardiovascular/Cerebrovascular
Description

Cardiovascular and cerebrovascular medications including indapamide tablets, nifedipine extended-release tablets (Type I and II), simvastatin tablets, perindopril indapamide tablets, and aniracetam dispersible tablets, supplied to hospitals and clinical settings for cardiovascular treatment.

2Analgesic Medications (镇痛药品类)
CategoryTherapeutic drug category - Analgesic
Description

Pain relief medications including paracetamol codeine tablets (Type I and II), lofentanyl tablets, and hydrocodone paracetamol tablets (exclusive product) for clinical pain management.

3Antitussive Medications (止咳药品类)
CategoryTherapeutic drug category - Antitussive
Description

Cough suppressant medications including compound licorice tablets for clinical cough suppression treatment.

4Narcotic Medications (麻醉药品类)
CategoryTherapeutic drug category - Narcotic/Anesthesia
Description

Narcotic medications including remifentanil hydrochloride for injection, sufentanil citrate injection, and midazolam injection, supplied as anesthesia agents for surgical and clinical use.

5Other Medications (其他药品类)
CategoryTherapeutic drug category - Psychiatric/Gastrointestinal
Description

Other pharmaceutical products including fumarate quetiapine extended-release tablets, fenghan ironing agent, and omeprazole enteric-coated tablets for psychiatric and gastrointestinal therapeutic areas.

6Active Pharmaceutical Ingredients / APIs (原料药)
CategoryActive pharmaceutical ingredient (API)
Description

Active pharmaceutical ingredients including nalbuphine hydrochloride, ketamine hydrochloride, and other controlled substance APIs for supply to downstream pharmaceutical manufacturers and internal formulation use.

7Suppository Products (栓剂)
CategoryTopical dosage form
Description

Suppository products including metronidazole suppositories, clotrimazole suppositories, acetaminophen suppositories, indomethacin suppositories, and terconazole vaginal suppositories (exclusive) for gynecological and pain management applications.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-05-12
Description

OSR Holdings mentioned ongoing discussions with Sinopharm as part of its strategic developments, alongside a potential $815 million milestone agreement with BCM Europe AG for its oncology drug candidate VXM01. Sinopharm is referenced as a Chinese state-owned pharmaceutical group in the context of potential market entry discussions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-19
Description

Woori IO Co., Ltd., a South Korea-based subsidiary of OSR Holdings (NASDAQ:OSRH), signed a mutual non-disclosure agreement with Sinopharm Group Beijing Huahong to evaluate potential regulatory, clinical, and commercial pathways for its non-invasive near-infrared glucose monitoring technology in China. The NDA establishes a formal framework for exchanging confidential information for evaluating pathways into China's diabetes market projected to exceed $12 billion by 2032. Sinopharm Group Beijing Huahong is a state-owned Chinese pharmaceutical company engaged in the diabetes care sector.

3国药乐仁堂唐山有限公司 (Sinopharm Lerentang Tangshan Co., Ltd.)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-05-08
Description

Sinopharm Group Industrial Co., Ltd.'s Fifth Party Branch conducted a joint party-building activity with the Second Party Branch of Sinopharm Lerentang Tangshan Co., Ltd., focusing on '党建引领促合作、交流互鉴共发展' (Party building leads cooperation, exchange and mutual learning for development). The collaboration aims to deepen party building integration with business operations, share party building experiences, and explore '党建+产业链' cooperation models for market resource integration, supply chain coordination, and regional market collaboration. Joint visits to the Communist Party History Exhibition Hall were conducted.

cnpicl.com
Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Large listed Chinese pharmaceutical group with diversified portfolio including CNS, cardiovascular, and anti-infective products; broadly comparable scale, channel access, and R&D capability profile, though more diversified into innovative biologics and oncology than Sinopharm Industrial.

2Shanghai Pharmaceuticals Holding
TypeBroad incumbent
Description

Central SOE-controlled pharmaceutical group under similar SASAC oversight as Sinopharm Industrial; broadly comparable state-owned pharma operator with overlapping distribution channels and cardiovascular, anti-infective, and API businesses.

3Hengrui Medicine
TypeBroad incumbent
Description

China's largest listed innovative pharmaceutical company with a broad portfolio across oncology, anesthesia, analgesics, and contrast media; relevant comparable for the anesthesia/analgesic overlap and as the benchmark for Chinese specialty pharma R&D intensity and pipeline.

4Tianjin Tianyao Pharmaceuticals
TypeRegional player
Description

State-owned Chinese pharmaceutical manufacturer focused on APIs, steroids, and selected finished formulations; directly comparable as a fellow Chinese state-owned API and finished dose manufacturer competing in similar institutional channels.

TypeBroad incumbent
Description

One of China's largest private pharmaceutical manufacturers with broad generic and innovative product coverage including cardiovascular and analgesic categories overlapping Sinopharm Industrial's portfolio; relevant comparable for scale and generic competition in shared therapeutic areas.

6Joincare Pharmaceutical Group
TypeBroad incumbent
Description

Mid-large Chinese pharmaceutical manufacturer with respiratory, cardiovascular, and specialty therapeutic areas including some controlled-substance products; relevant comparable for portfolio scale and direct competition in cardiovascular and analgesic categories.

TypeDirect peer
Description

Specialized Chinese CNS-focused pharmaceutical manufacturer producing psychiatric drugs, anesthetics, and related dosage forms; directly comparable in the psychotropic and controlled-substance product overlap with Sinopharm Industrial's psychiatric medication pipeline.

8China Resources Pharmaceutical Group
TypeBroad incumbent
Description

State-owned pharmaceutical conglomerate under China Resources with generics, APIs, and finished dosage forms across multiple therapeutic areas; comparable as a parallel state-owned platform with similar distribution advantages and regulatory relationships.

TypeOthers
Description

Chinese API and intermediate manufacturer serving global generic companies with vertically integrated production; relevant as a comparable Chinese API player whose capabilities overlap with Sinopharm Industrial's API manufacturing business for both internal use and third-party sale.

10Humanwell Healthcare Group
TypeDirect peer
Description

Major Chinese pharmaceutical manufacturer with a strong portfolio in narcotic APIs (codeine, morphine derivatives) and finished dosage forms; the most directly comparable controlled-substance manufacturer and the closest head-to-head competitor in Sinopharm Industrial's core therapeutic areas of anesthesia and analgesia.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sinopharm

Pharmaceutical Manufacturingcnpicl.com

Sinopharm Group Industrial Co., Ltd. is a Chinese state-designated pharmaceutical manufacturer producing narcotic, psychotropic, anesthetic, and analgesic APIs and formulations, operating dual Beijing-Hebei production bases to supply hospitals, retail pharmacies, and drug manufacturers across China.

What Sinopharm does

Sinopharm Group Industrial Co., Ltd. (国药集团工业有限公司) is a Chinese state-designated pharmaceutical manufacturer founded in 1991 and headquartered in Shunyi, Beijing. It operates as a wholly-owned subsidiary of Shanghai Modern Pharmaceutical Co., Ltd. (国药现代, Shanghai Stock Exchange ticker 600420) under China National Pharmaceutical Group Co., Ltd. (Sinopharm Group), and is ultimately owned by China's State-owned Assets Supervision and Administration Commission (SASAC). The company operates two production bases — Shunyi (Beijing, approximately 100,000 square meters of total land area) and Langfang (Hebei Province, secondary manufacturing base) — and is the national designated manufacturer of narcotic and psychotropic pharmaceutical products in China.

The company's product portfolio spans anesthesia, analgesia, antitussive, cardiovascular, psychiatric, gynecological suppository, and other therapeutic areas, produced under an integrated API-formulation production system. Annual production capacity includes approximately 60 tons of active pharmaceutical ingredients, 50 billion solid oral tablets, 23 million units of small-volume injections and lyophilized powder injections, and 4 million units of oral solutions, plus suppositories and other dosage forms. Core technology platforms include sustained-release microspheres, microreactor technology, chromatographic separation and purification, and impurity reference material preparation, with multiple national invention patents in anesthesia and psychotropic drugs. Recent new product launches (2025-2026) include hydromorphone hydrochloride injection (second domestic manufacturer in China), quetiapine fumarate extended-release tablets (200mg and 300mg), penehyclidine hydrochloride injection, and several new API registrations including ketamine hydrochloride and nalbuphine hydrochloride.

The company's business model is sales-led B2B distribution, organized through four regional sales divisions covering North, East, West, and South China, plus dedicated product-line divisions for anesthesia, analgesics, and commercial management. Revenue is generated through direct sales to domestic healthcare institutions (hospitals, clinics) and retail pharmacy terminals, as well as API/intermediate supply to downstream pharmaceutical manufacturers, with pricing negotiated through government tendering, reimbursement lists, and institutional purchasing agreements. A separate revenue stream arises from registration certificates and consistent-evaluation approvals granted by China's National Medical Products Administration (NMPA), which expand the company's marketable product portfolio.

Sinopharm firmographics

Firmographics
Name
Sinopharm
Legal name
国药集团工业有限公司
Website
https://cnpicl.com
Company type
Public
Founded year
1991
Operating status
Operating
Headcount range
11–50 employees
Short description
Sinopharm Group Industrial Co., Ltd. is a Chinese state-designated pharmaceutical manufacturer producing narcotic, psychotropic, anesthetic, and analgesic APIs and formulations, operating dual Beijing-Hebei production bases to supply hospitals, retail pharmacies, and drug manufacturers across China.
Ownership category
akta.pro rank

Sinopharm industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAHAD
Controlled Substances / DEA-Scheduled API Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIABAH
Generic Finished Dosage Form (FDF) Manufacturing
SECONDARYHLAIAJAO
Compounding Ingredient & API Distributors (Pharma Supply)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Distribution & Wholesaling

Keywords

  • Pharmaceutical manufacturing
  • Narcotic drug production
  • Active pharmaceutical ingredients
  • Anesthesia and analgesia
  • Controlled substance manufacturing

Where Sinopharm is headquartered

Location

Headquarters

HQ city
Beijing
HQ country
China
HQ region
Asia

Offices2 records

Markets served

Sinopharm business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Manufacturing and Sales: Manufactures and sells pharmaceutical products including active pharmaceutical ingredients (APIs), solid oral formulations (50 billion tablets annually), small-volume injections and lyophilized powder injections (23 million units annually), oral solutions (4 million units annually), suppositories, and other dosage forms. Products span anesthesia, analgesia, antitussive, cardiovascular, psychiatric, and other therapeutic areas. Revenue is generated through direct sales to healthcare institutions and retail pharmacy distribution networks across China.
  2. New Drug Product Registrations: Generates revenue through registration certificates for new drug products and API approvals from China's National Medical Products Administration (NMPA), including consistent evaluation certifications for generic drugs, expanding the company's product portfolio and market competitiveness.

Go-to-market motion1 record

Distribution channels7 records

Marketing channels3 records

Sinopharm product offering

Product offering

Core offering

Sinopharm Group Industrial Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) and finished pharmaceutical products including narcotic and psychotropic drugs, anesthesia agents, analgesics, antitussives, cardiovascular medications, and gynecological suppositories across multiple dosage forms (solid oral tablets, injections, oral solutions, suppositories). The company holds national designated manufacturer status for narcotic drugs in China and supplies healthcare institutions and retail pharmacy networks through regional sales divisions covering North, East, West, and South China. Production is supported by four proprietary technology platforms including sustained-release microspheres, microreactors, chromatographic purification, and impurity reference material preparation.

Product overview

Sinopharm Group Industrial Pharmaceutical Co., Ltd. (国药集团工业有限公司) is a state-designated narcotic drug manufacturing enterprise and wholly-owned subsidiary of Shanghai Sine Pharmaceutical Co., Ltd. (stock code: 600420) under China National Pharmaceutical Group (Sinopharm). The company operates two production bases in Shunyi and Langfang with approximately 100,000 square meters. Annual production capacity includes nearly 60 tons of APIs, 5 billion tablets of solid oral formulations, 23 million units of small-volume injections and freeze-dried powder injections, 4 million units of oral solutions, plus various other dosage forms including suppositories and ironing agents. The company's product portfolio centers on 'one narcotics, three analgesics, one戒 (addiction treatment)' principle, establishing an integrated production system combining narcotic APIs with preparations and full coverage of various dosage forms. The company focuses on anesthesia, analgesia, cough suppression, gynecological suppositories, and cardiovascular therapeutic areas. The company operates with raw material medicine and narcotic preparations supporting each other, with comprehensive dosage form coverage.

Differentiator

Problem solved

Functional benefit

Products and services

  • Cardiovascular and Cerebrovascular Medications (心脑血管类药品) Cardiovascular and cerebrovascular medications including indapamide tablets, nifedipine extended-release tablets (Type I and II), simvastatin tablets, perindopril indapamide tablets, and aniracetam dispersible tablets, supplied to hospitals and clinical settings for cardiovascular treatment.
  • Analgesic Medications (镇痛药品类) Pain relief medications including paracetamol codeine tablets (Type I and II), lofentanyl tablets, and hydrocodone paracetamol tablets (exclusive product) for clinical pain management.
  • Antitussive Medications (止咳药品类) Cough suppressant medications including compound licorice tablets for clinical cough suppression treatment.
  • Narcotic Medications (麻醉药品类) Narcotic medications including remifentanil hydrochloride for injection, sufentanil citrate injection, and midazolam injection, supplied as anesthesia agents for surgical and clinical use.
  • Other Medications (其他药品类) Other pharmaceutical products including fumarate quetiapine extended-release tablets, fenghan ironing agent, and omeprazole enteric-coated tablets for psychiatric and gastrointestinal therapeutic areas.
  • Active Pharmaceutical Ingredients / APIs (原料药) Active pharmaceutical ingredients including nalbuphine hydrochloride, ketamine hydrochloride, and other controlled substance APIs for supply to downstream pharmaceutical manufacturers and internal formulation use.
  • Suppository Products (栓剂) Suppository products including metronidazole suppositories, clotrimazole suppositories, acetaminophen suppositories, indomethacin suppositories, and terconazole vaginal suppositories (exclusive) for gynecological and pain management applications.

Quantifiable outcome

  • Annual production capacity of ~60 tons of active pharmaceutical ingredients and 50 billion solid oral tablets
  • +2 more outcomes

Companies that use Sinopharm

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Sinopharm technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Sinopharm partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor and core.

  • Sinopharm (ongoing discussions)minorStrategic or Co-development Partner · 12 May 2026OSR Holdings mentioned ongoing discussions with Sinopharm as part of its strategic developments, alongside a potential $815 million milestone agreement with BCM Europe AG for its oncology drug candidate VXM01. Sinopharm is referenced as a Chinese state-owned pharmaceutical group in the context of potential market entry discussions.
  • Sinopharm Group Beijing Huahong (中国医药集团有限公司北京华鸿)coreStrategic or Co-development Partner · 19 March 2026Woori IO Co., Ltd., a South Korea-based subsidiary of OSR Holdings (NASDAQ:OSRH), signed a mutual non-disclosure agreement with Sinopharm Group Beijing Huahong to evaluate potential regulatory, clinical, and commercial pathways for its non-invasive near-infrared glucose monitoring technology in China. The NDA establishes a formal framework for exchanging confidential information for evaluating pathways into China's diabetes market projected to exceed $12 billion by 2032. Sinopharm Group Beijing Huahong is a state-owned Chinese pharmaceutical company engaged in the diabetes care sector.
  • 国药乐仁堂唐山有限公司 (Sinopharm Lerentang Tangshan Co., Ltd.)coreStrategic or Co-development Partner · 8 May 2025Sinopharm Group Industrial Co., Ltd.'s Fifth Party Branch conducted a joint party-building activity with the Second Party Branch of Sinopharm Lerentang Tangshan Co., Ltd., focusing on '党建引领促合作、交流互鉴共发展' (Party building leads cooperation, exchange and mutual learning for development). The collaboration aims to deepen party building integration with business operations, share party building experiences, and explore '党建+产业链' cooperation models for market resource integration, supply chain coordination, and regional market collaboration. Joint visits to the Communist Party History Exhibition Hall were conducted.

Scale indicators5 records

Recent moves12 records

Expansion highlights5 records

Sinopharm competitors and assessment

Company assessment

Broad incumbents

  • CSPC Pharmaceutical Group: Large listed Chinese pharmaceutical group with diversified portfolio including CNS, cardiovascular, and anti-infective products; broadly comparable scale, channel access, and R&D capability profile, though more diversified into innovative biologics and oncology than Sinopharm Industrial.
  • Shanghai Pharmaceuticals Holding: Central SOE-controlled pharmaceutical group under similar SASAC oversight as Sinopharm Industrial; broadly comparable state-owned pharma operator with overlapping distribution channels and cardiovascular, anti-infective, and API businesses.
  • Hengrui Medicine: China's largest listed innovative pharmaceutical company with a broad portfolio across oncology, anesthesia, analgesics, and contrast media; relevant comparable for the anesthesia/analgesic overlap and as the benchmark for Chinese specialty pharma R&D intensity and pipeline.
  • Yangtze River Pharmaceutical Group: One of China's largest private pharmaceutical manufacturers with broad generic and innovative product coverage including cardiovascular and analgesic categories overlapping Sinopharm Industrial's portfolio; relevant comparable for scale and generic competition in shared therapeutic areas.
  • Joincare Pharmaceutical Group: Mid-large Chinese pharmaceutical manufacturer with respiratory, cardiovascular, and specialty therapeutic areas including some controlled-substance products; relevant comparable for portfolio scale and direct competition in cardiovascular and analgesic categories.
  • China Resources Pharmaceutical Group: State-owned pharmaceutical conglomerate under China Resources with generics, APIs, and finished dosage forms across multiple therapeutic areas; comparable as a parallel state-owned platform with similar distribution advantages and regulatory relationships.

Regional players

  • Tianjin Tianyao Pharmaceuticals: State-owned Chinese pharmaceutical manufacturer focused on APIs, steroids, and selected finished formulations; directly comparable as a fellow Chinese state-owned API and finished dose manufacturer competing in similar institutional channels.

Direct peers

  • Nhwa Pharmaceutical: Specialized Chinese CNS-focused pharmaceutical manufacturer producing psychiatric drugs, anesthetics, and related dosage forms; directly comparable in the psychotropic and controlled-substance product overlap with Sinopharm Industrial's psychiatric medication pipeline.
  • Humanwell Healthcare Group: Major Chinese pharmaceutical manufacturer with a strong portfolio in narcotic APIs (codeine, morphine derivatives) and finished dosage forms; the most directly comparable controlled-substance manufacturer and the closest head-to-head competitor in Sinopharm Industrial's core therapeutic areas of anesthesia and analgesia.

Others

  • Apeloa Pharmaceutical: Chinese API and intermediate manufacturer serving global generic companies with vertically integrated production; relevant as a comparable Chinese API player whose capabilities overlap with Sinopharm Industrial's API manufacturing business for both internal use and third-party sale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Sinopharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sinopharm leadership team

Management profile

Number of profiles

Profiles9 records

Sinopharm subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Sinopharm funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sinopharm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sinopharm

What does Sinopharm do?

Sinopharm Group Industrial Co., Ltd. manufactures and sells active pharmaceutical ingredients (APIs) and finished pharmaceutical products including narcotic and psychotropic drugs, anesthesia agents, analgesics, antitussives, cardiovascular medications, and gynecological suppositories across multiple dosage forms (solid oral tablets, injections, oral solutions, suppositories). The company holds national designated manufacturer status for narcotic drugs in China and supplies healthcare institutions and retail pharmacy networks through regional sales divisions covering North, East, West, and South China. Production is supported by four proprietary technology platforms including sustained-release microspheres, microreactors, chromatographic purification, and impurity reference material preparation.

Is Sinopharm a public or private company?

Sinopharm is a public company. It is classified as corporate owned and is currently operating.

When was Sinopharm founded?

Sinopharm was founded in 1991. It employs 11 to 50 people.

Where is Sinopharm based?

Sinopharm is headquartered in Beijing, China, in the Asia region.

How does Sinopharm make money?

Two revenue lines are on record. Pharmaceutical Manufacturing and Sales are the primary driver. The others are new Drug Product Registrations.

Who are Sinopharm's main competitors?

Broad incumbents on record are CSPC Pharmaceutical Group, Shanghai Pharmaceuticals Holding, Hengrui Medicine, Yangtze River Pharmaceutical Group, Joincare Pharmaceutical Group and China Resources Pharmaceutical Group. Tianjin Tianyao Pharmaceuticals is listed as a regional player. Direct peers are Nhwa Pharmaceutical and Humanwell Healthcare Group. Apeloa Pharmaceutical is listed as an others.

Does Sinopharm have an API?

No public API is recorded for Sinopharm.

What industry is Sinopharm in?

Sinopharm's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAGAHAD, Controlled Substances / DEA-Scheduled API Manufacturing, with a secondary code of HLAIABAH, Generic Finished Dosage Form (FDF) Manufacturing. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooHBM Holdings (SEHK:2142) Teams Up With Sinopharm To Build A Biologics ConsortiumHBM Holdings (SEHK:2142), through its subsidiary Harbour BioMed, has entered a strategic collaboration with Sinopharm to create an Innovation R&D Consortium focused on biologic therapies for oncology and immune-mediated diseases. Harbour BioMed contributes its Harbour Mice fully human antibody platform and AI-powered discovery capabilities, while Sinopharm handles clinical development, large-scale manufacturing, and commercialization. The partnership extends HBM Holdings' existing strategy of collaborating with global pharma companies such as AstraZeneca and Bristol Myers Squibb, positioning the company more directly alongside larger competitors including Roche, Novartis, and AbbVie in these therapeutic areas.AijournHarbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D ConsortiumHarbour BioMed announced a strategic collaboration with China National Pharmaceutical Group Co., Ltd. (Sinopharm) to establish the Sinopharm–Harbour BioMed Innovation Consortium for advancing collaborative R&D of innovative biologics, with a focus on oncology and immune-mediated inflammatory diseases. Under the agreement, Harbour BioMed will contribute its globally leading Harbour Mice fully human antibody technology platform and AI-enabled drug discovery capabilities, while Sinopharm will provide clinical development, large-scale manufacturing, and commercialization expertise. The two parties will jointly fund R&D activities and share product rights according to mutually agreed terms.YahooHarbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D ConsortiumHarbour BioMed and Sinopharm have entered into a strategic collaboration to establish the Sinopharm-Harbour BioMed Innovation Consortium for advancing collaborative R&D of innovative biologics in oncology and immune-mediated inflammatory diseases. Under the agreement, Harbour BioMed will contribute its Harbour Mice fully human antibody technology platform and AI-enabled drug discovery capabilities, while Sinopharm will provide clinical development, large-scale manufacturing, and commercialization expertise. The two parties will jointly fund R&D activities and share product rights according to mutually agreed terms.PR Newswire APACHarbour BioMed and Sinopharm Enter Strategic Collaboration to Establish Innovation R&D ConsortiumHarbour BioMed and Sinopharm have entered into a strategic collaboration to establish the Sinopharm-Harbour BioMed Innovation Consortium for advancing collaborative research and development of innovative biologics. Under the agreement, Harbour BioMed will contribute its globally leading Harbour Mice® fully human antibody technology platform and AI-enabled drug discovery capabilities, while Sinopharm will provide clinical development, large-scale manufacturing, and commercialization expertise, with both parties jointly funding R&D activities and sharing product rights. The collaboration will focus on oncology, immune-mediated inflammatory diseases and other therapeutic areas, with the goal of accelerating innovative drug development and expanding patient access to treatment options.Stock TitanWoori IO signs Sinopharm NDA to assess China marketWoori IO Co., Ltd., a South Korea-based subsidiary of OSR Holdings (NASDAQ:OSRH), has signed a mutual non-disclosure agreement with Sinopharm Group Beijing Huahong to evaluate potential regulatory, clinical, and commercial pathways for its noninvasive near-infrared glucose monitoring technology in China. The NDA establishes a formal framework for exchanging confidential information and represents an early-stage strategic engagement in China's diabetes market, which is projected to exceed $12 billion by 2032. Woori IO's CEO indicated the company is also in discussions with healthcare organizations and distribution partners across multiple regions.PR NewswireChina Review Studio e Chinese Red Cross Foundation lançam documentário "Generation Vax" para transmissão internacionalChina Review Studio and the Chinese Red Cross Foundation launched the documentary "Generation Vax" to highlight China's contributions to COVID-19 vaccine research, production, and international clinical trials. The film details collaborations such as the Project S trial in Brazil with SINOVAC Biotechnology and the large-scale Sinopharm study in the UAE, aiming to promote global scientific cooperation.PR NewswireCGTN : les vaccins chinois COVID-19 se sont avérés sûrs et efficaces grâce aux essais et aux donnéesChinese COVID-19 vaccines have been proven safe and effective through clinical trials and real-world data, with over 1.3 billion people in China receiving more than 3.4 billion doses and a reported serious adverse event rate of 0.07 per 100,000 doses. Three Chinese vaccine products are listed on the WHO Emergency Use Listing, with Sinovac's CoronaVac demonstrating 83.5% efficacy in a Turkish Phase III trial and Sinopharm's vaccine showing 79% efficacy against hospitalization in a multinational study. China has exported over 2.2 billion doses to more than 120 countries and international organizations, fulfilling what the article describes as international responsibility during a period when developed nations like the US and UK had restricted vaccine exports.PR NewswireCGTN: badania i dane potwierdzają bezpieczeństwo i skuteczność chińskich szczepionek przeciwko COVID-19Clinical trial data and global database records from early 2023 confirm the safety and efficacy of Chinese COVID-19 vaccines, which China highlighted as an undeniable achievement in pandemic response. China developed 13 different vaccine types using diverse technical platforms including inactivated virus, viral vector, and subunit vaccines, with three receiving WHO emergency use authorization. The vaccines were distributed to over 120 countries and international organizations totaling 2.2 billion doses, with Sinovac's CoronaVac demonstrating 83.5% efficacy in Turkish trials and Sinopharm showing 79% efficacy against severe cases requiring hospitalization in WHO-recommended multi-country Phase III trials.PR NewswireCGTN: Čínske vakcíny proti ochoreniu COVID-19 sa na základe klinických skúšaní a údajov ukázali ako bezpečné a účinnéChina's COVID-19 vaccines have been proven safe and effective based on clinical trials and real-world data, with 13 vaccines now available using multiple technology platforms including mRNA, inactivated virus, viral vector, and subunit protein approaches. As of January 12, 2023, more than 1.3 billion people in China had received over 3.4 billion doses, with vaccines like Sinopharm showing 79% efficacy and Sinovac's CoronaVac demonstrating 83.5% efficacy in Turkish trials. China has donated and exported over 2.2 billion doses of COVID-19 vaccines to more than 120 countries and international organizations, fulfilling what the article describes as the country's international responsibility.PR NewswireCGTN: Las vacunas de China contra la COVID-19 han demostrado ser seguras y eficaces mediante ensayos y datosChina's COVID-19 vaccines have demonstrated safety and efficacy through clinical trials and real-world data, with over 3.4 billion doses administered to more than 1.3 billion people as of January 12, 2023. Three Chinese vaccines are on the WHO emergency use list, with Sinopharm showing 79% efficacy against hospitalization in multinational Phase III trials and Sinovac's CoronaVac demonstrating 83.5% efficacy in a Turkish trial of over 10,000 participants. China has exported and donated more than 2.2 billion doses to over 120 countries and international organizations, fulfilling what the article describes as international responsibility.